A Randomized, Non-Comparative, Phase II Study of Maintenance OSE2101 Vaccine Alone or in Combination with Nivolumab (nivo) or FOLFIRI after Induction with FOLFIRINOX in Patients (pts) with Advanced Pancreatic Ductal Adenocarcinoma (apdac): First Interim Results of the TEDOPAM GERCOR D17-01 PRODIGE 63 STUDY.
Journal of Clinical Oncology(2022)
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要